Cannabis Sector Kicks Off March With a Blast of Q4 Earnings

Seven different cannabis companies reported earnings last week

facebook twitter linkedin


Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

The world of cannabis saw massive growth in 2021 and 18 states plus D.C. officially legalized the adult-use of cannabis by the end of the year. Thirty-one states plus D.C. had taken decriminalization measures regarding cannabis by the end of 2021. As of late 2021, marijuana is classified at the U.S. federal level as a Schedule I substance under the Controlled Substances Act. In other words, cultivating, distributing, and possessing cannabis remains illegal at the federal level.

In addition, here is a quick summary of the major (and action-worthy!) cannabis stock news from this week:

Village Farms International, Inc. (NASDAQ:VFF) released its fourth quarter of 2021 financial results on Tuesday, March 1. According to Village Farms' CEO, "In the fourth quarter, we once again saw strong year-over-year growth in sales and adjusted EBITDA, with positive adjusted EBITDA contributions from each of our Canadian Cannabis, US Cannabis and Village Farms Fresh (produce) businesses for the second consecutive quarter."

Cronos Group Inc. (NASDAQ:CRON) also released fourth quarter of 2021 financial results on March 1. Per Cronos Group's CEO, "Our fourth quarter 2021 results indicate positive momentum, which we will look to carry forward as we begin to implement our strategic and operational realignment initiatives. As we look to 2022, we will continue to realign Cronos Group's organizational structure to match our strategy, with a primary focus on adult-use products and elevating our brands through rare cannabinoids.”

The Valens Company Inc. (NASDAQ:VLNS) released fourth quarter of 2021 financial results on Tuesday. According to Valens' CEO, "This quarter showcases the progress we have made in our business plan in key areas despite a competitive and challenging operating environment in Canada and globally. Net revenue slightly declined quarter-over-quarter, as we completed the transition of our B2B business to align with the 'fewer, bigger, better' strategy and was negatively impacted by the floods in British Columbia which resulted in supply chain disruptions. However, in our two key revenue segments, we are very pleased with the industry leading growth in provincial sales revenue and the full quarter revenue generated by our Green Roads US CBD business. With the B2B transition largely behind us, we expect to have more sustained growth in 2022."

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released fourth quarter of 2021 financial results on Tuesday, March 1. Per Zynerba's CEO, “In 2022, we look to build on last year’s progress as we continue to enroll patients in our confirmatory pivotal Phase 3 trial in Fragile X syndrome, initiate a Phase 3 program in autism spectrum disorder and report topline results in our Phase 2 trial in 22q11.2 deletion syndrome. We are committed to achieving our goal of bringing the first pharmaceutical product indicated for the treatment of behavioral symptoms of Fragile X syndrome to market, as well as advancing Zygel in other rare and near rare neuropsychiatric indications.”

On Tuesday, Organigram Holdings Inc. (NASDAQ:OGI) announced that it had received an investment from BAT of $6.3 million CAD, increasing BAT's equity position in Organigram up to 19.5%.

GrowGeneration Corp. (NASDAQ:GRWG) released fourth quarter of 2021 financial results on Tuesday, March 1. Revenues increase nearly $30 million year-over-year in Q4 and over $200 million year-over-year compared to 2020. According to GrowGen's CEO,  "In order to position the company for 2022 and beyond, we have made several strategic decisions to drive margin improvements and EBITDA. As of Dec. 31, 2021 our balance sheet remains strong with $81 million of available liquidity. Given our view of the business today and the continued challenges across the US market, we expect to generate full year revenue of $415 to $445 million in 2022."

 

Hydrofarm Holdings Group, Inc. (NASDAQ:HYFM) released fourth quarter of 2021 financial results on Tuesday. HYFM reported a 26% jump in net sales in Q4 of 2021 compared to Q4 of 2020. For the full year of 2021, Hydrofarm holding reported a 40% increase in net sales compared to 2020. Per HYFM's CEO, in late 2021 and early 2022 we acted on several margin enhancing initiatives to reduce costs and mitigate inflationary pressures, including increasing prices where appropriate, as well as right-sizing our headcount as we have begun realizing synergies from our 2021 acquisitions. Together with our unique position as a leading ‘picks and shovels' supplier to the CEA industry and a strong balance sheet that can support future growth, we remain excited about our prospects in 2022 and beyond."

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its fourth quarter of 2021 financial results on Tuesday. According to Jazz's CEO, "2021 was a transformative year for Jazz, delivering over $3 billion in revenue for the first time. Our talented team achieved our goal of five key launches through 2020 and 2021, delivering innovative medicines to patients in critical need. We also acquired and integrated GW Pharmaceuticals, which expanded our commercial portfolio with Epidiolex®, enhanced our R&D capabilities and talent, and added the industry-leading GW cannabinoid platform.

On Wednesday, Clever Leaves Holdings Inc. (NASDAQ:CLVR) confirmed that it had signed an internationall sales agreement with Foliumed and subsidiary Fidelio for a period of one year. Through Clever Leaves providing this German cannabis company with product, Fidelio will be able to speed up production. According to CLVR's CEO, “Leveraging our Colombian operation to build and maintain relationships throughout the cannabinoid and pharmaceutical industry is incredibly important to us."

Vessel, a brand under the Flora Growth Corp. (NASDAQ:FLGC), confirmed the execution of a distribution agreement with JustCBD's Speedy to launch cash-and-carry distribution centers. This will be Vessel's first step into traditional smoke shop channels and Vessel plans to create new products specifically for this distribution arrangement.  According to JustCBD CEO, “The Vessel team designs excellent customer experiences, and whether through e-commerce or traditional wholesale, the products are always well received by customers. We see this agreement as the first of many where we leverage JustCBD’s existing distribution network and Flora’s diverse product portfolio to amplify growth for our combined Company.”

Manitoba Harvest, a wholly-owned subsidiary of cannabis brand Tilray Brands, Inc. (NASDAQ:TLRY), plans to release its brand new hemp products at the upcoming Natural Products Expo West. According to the VP of Marketing at Manitoba Harvest, “Hemp has been one of the most misunderstood plants for decades, and we’re thrilled to see consumers beginning to understand its nutritional value. These new items take full advantage of Hemp’s Protein and Omega content and will be a perfect option for consumers looking to enhance their wellness routine."

Clever Leaves Holdings Inc. (NASDAQ:CLVR) confirmed it had signed a 4-year and $7.8 million supply agreement with Australian Natural Therapeutics Group (ANTG). According to the terms of the agreement, CLVR will provide CBD isolate and THC crude oil from Colombia as well as THC dried flower from Portugal. According to Clever Leaves' CEO, “Australia is a rapidly expanding market, and increasing product shipments to the country allows Clever Leaves to accelerate market growth further. ANTG’s research focus, pharmaceutical certifications and distribution capabilities are aligned with our mission to produce high-quality cannabinoid-based medicinal treatments that can meet patient needs.”

*NEW CANNABIS AND PSYCHEDELICS STOCK ALERT* Incannex Healthcare Limited (NASDAQ:IXHL) began trading at the opening bell on Monday, March 1, on the Nasdaq Global Market. According to Incannex CEO, "The ringing of the closing bell to commemorate the listing of our ADSs was a milestone for Incannex, as we advance our pipeline of novel synthetic cannabinoid and psychedelic agents through the clinic. Listing on Nasdaq will help increase our visibility with international investors and clinical research facilities. We look forward to continuing our strategy of pursuing U.S. Food and Drug Administration approval for all of our therapies and to bringing these innovative medicines to patients in need."

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners